Supplemental Dental, Vision Benefits May Not Justify MA Payments for VA-Covered Veterans
Published: May 22nd 2025 | Updated: May 22nd 2025Veterans primarily receiving care through the Department of Veterans Affairs (VA) similarly used dental and vision services under Medicare Advantage (MA) and traditional Medicare, challenging the justification for full MA capitated payments based on supplemental benefits.
Read More
Health Policy in Flux: Trump Administration Updates
Published: May 20th 2025 | Updated: May 20th 2025HHS announces it is taking steps to implement President Trump’s Executive Order on prescription drug pricing. Keep up with the latest moves made in health policy under President Donald Trump's second administration. This timeline will be updated as orders and policy progress.
Read More
Is the US Headed for an Infectious Disease Pandemic?
May 20th 2025In an era that FDA Commissioner Marty Makary, MD, MPH, calls an "epidemic of distrust" toward health institutions, previously contained disease rates are rapidly rising, and vaccination rates are proceeding in the opposite direction.
Read More
Effects of Maryland’s All-Payer Model on Elective Joint Replacement Surgery
The Maryland All-Payer Model was associated with an increase in population-based rates of elective major joint replacements, with a more pronounced effect observed in Maryland-only hospitals.
Read More
Health Outcomes Under Full-Risk Medicare Advantage vs Traditional Medicare
Physician groups under 2-sided risk–based Medicare Advantage provide care associated with higher quality and efficiency compared with care by these same groups under fee-for-service Medicare.
Read More
Black Youths Overlabeled High Risk in Mental Health Emergencies
May 9th 2025Despite similar scores on an aggression risk evaluation tool in a pediatric emergency department, Black youths were significantly more likely to be labeled with a high aggression risk behavioral health flag in their electronic health records compared with White youths.
Read More
Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD
May 9th 2025Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.
Read More
Early Identification of MASLD/MASH Saves Lives: Naim Alkhouri, MD
May 6th 2025Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase patient access, but also improve the overall wellbeing, experience, and outcomes for this population.
Watch
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials
May 6th 2025The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Read More
Managed Care Reflections: A Q&A With John Michael O’Brien, PharmD, MPH
May 5th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The May issue features a conversation with John Michael O’Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council. This interview has been lightly edited for clarity.
Read More